|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
The effect of theobromine supplementation on anthropometric indices, glycemic indices, cardiovascular risk factors, and genes expression of PPARa and Sirt1 in subjects with metabolic syndrome.
A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough
The purpose of this study is to investigate the effect of BC1036 (theobromine) on cough-related quality of life and cough severity following 2 weeks' treatment.
A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough
100 Clinical Results associated with PDE4B x A1R x A2aR
100 Translational Medicine associated with PDE4B x A1R x A2aR
0 Patents (Medical) associated with PDE4B x A1R x A2aR